Alto Neuroscience Inc.’s recently made public that its CHIEF MEDICAL OFFICER Savitz Adam acquired Company’s shares for reported $0.15 million on Jul 09 ’24. In the deal valued at $12.60 per share,12,069 shares were bought. As a result of this transaction, Savitz Adam now holds 36,920 shares worth roughly $0.5 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Savitz Adam bought 2,931 shares, generating $38,748 in total proceeds. Upon buying the shares at $13.22, the CHIEF MEDICAL OFFICER now owns 39,851 shares.
Before that, Smith Nicholas Conrad bought 6,150 shares. Alto Neuroscience Inc. shares valued at $100,628 were divested by the CHIEF FINANCIAL OFFICER at a price of $16.36 per share. As a result of the transaction, Smith Nicholas Conrad now holds 26,866 shares, worth roughly $0.36 million.
Wedbush initiated its Alto Neuroscience Inc. [ANRO] rating to an Outperform in a research note published on September 03, 2024; the price target was $29. A number of analysts have revised their coverage, including William Blair’s analysts, who began to cover the stock in late February with a ‘”an Outperform”‘ rating. TD Cowen began covering ANRO with “an Outperform” recommendation on February 27, 2024. Stifel started covering the stock on February 27, 2024. It rated ANRO as “a Buy”.
Price Performance Review of ANRO
On Friday, Alto Neuroscience Inc. [NYSE:ANRO] saw its stock jump 14.65% to $13.54. Over the last five days, the stock has gained 29.57%. Alto Neuroscience Inc. shares have fallen nearly -34.59% since the year began.
Levels Of Support And Resistance For ANRO Stock
The 24-hour chart illustrates a support level at 12.43, which if violated will result in even more drops to 11.31. On the upside, there is a resistance level at 14.12. A further resistance level may holdings at 14.69. The Relative Strength Index (RSI) on the 14-day chart is 62.24, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.79, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 0.99%. Stochastics %K at 64.30% indicates the stock is a holding.
How much short interest is there in Alto Neuroscience Inc.?
A steep rise in short interest was recorded in Alto Neuroscience Inc. stocks on 2024-09-30, growing by 1.05 million shares to a total of 4.12 million shares. Yahoo Finance data shows the prior-month short interest on 2024-08-30 was 3.06 million shares. There was a rise of 25.61%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on February 27, 2024 when Robert W. Baird began covering the stock and recommended ‘”an Outperform”‘ rating along with a $32 price target.
